Clinical Trial

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn about the safety of NouvNeu001 injection in Early-onset Parkinson's Disease (EOPD) patients. It will also learn about the effects of NouvNeu001 treatment. The main questions it aims to answer are: What medical problems do participants have when transplanting NouvNeu001 into bilateral putamen using stereotactic neurosurgery? Does injection of NouvNeu001 improve the motor function and non-motor function in participants? Participants will: Be injectioned the NouvNeu001 into bilateral putamen using stereotactic neurosurgery. Take immunosuppressants to prevent potential immune rejection for 24 to 36 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-19.
Trial Details
NCT Number NCT06608355
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Early-onset Parkinson's Disease
Enrollment 6 participants
Start Date 2024-08-23
Primary Completion 2026-04 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-11-07